OncoSec Medical has dosed the first patient in the OMS-104 phase 2 clinical trial, which is evaluating TAVO (tavokinogene telseplasmid) in combination with OPDIVO (nivolumab) as a neoadjuvant therapy for melanoma. TAVO is OncoSec Medical’s intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy, which is intended to be administered using its gene delivery platform (gene electrotransfer). On […]
January 10, 2021No CommentRead More
British pharma company Clinigen has agreed to buy the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) from Swiss pharma company Novartis in an all-cash transaction that could be worth up to $210 million. Proleukin is an FDA approved drug for metastatic melanoma and metastatic renal cell carcinoma. Clinigen has agreed to make the payments […]
Continue reading …